X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9) 9
female (6) 6
male (6) 6
middle aged (6) 6
adult (5) 5
drug therapy (5) 5
drug therapy, combination (5) 5
dosage and administration (4) 4
hepatitis c (4) 4
hepatitis c, chronic - drug therapy (4) 4
hiv infections - drug therapy (4) 4
index medicus (4) 4
abridged index medicus (3) 3
anti-hiv agents - therapeutic use (3) 3
antiviral agents (3) 3
antiviral agents - administration & dosage (3) 3
antiviral agents - adverse effects (3) 3
cd4-positive t-lymphocytes - virology (3) 3
hepacivirus - genetics (3) 3
hepatitis c, chronic - virology (3) 3
hiv (3) 3
hiv infection (3) 3
hiv protease inhibitors - therapeutic use (3) 3
infections (3) 3
interferon-alpha - administration & dosage (3) 3
medicine, general & internal (3) 3
polyethylene glycols - administration & dosage (3) 3
protease inhibitors (3) 3
research (3) 3
ribavirin (3) 3
sofosbuvir (3) 3
telaprevir (3) 3
uridine monophosphate - analogs & derivatives (3) 3
adolescent (2) 2
aged (2) 2
anti-hiv agents (2) 2
anti-hiv agents - administration & dosage (2) 2
antiviral agents - therapeutic use (2) 2
benzoates - pharmacokinetics (2) 2
biological sciences (2) 2
boceprevir (2) 2
ccr5 (2) 2
ccr5 receptor antagonists (2) 2
clinical trials (2) 2
combination (2) 2
dna, viral - genetics (2) 2
double-blind method (2) 2
drug interactions (2) 2
genotype (2) 2
haart therapy (2) 2
health aspects (2) 2
hepatitis (2) 2
highly active antiretroviral therapy (2) 2
hiv infections - immunology (2) 2
hiv protease inhibitors - administration & dosage (2) 2
hiv-1 - isolation & purification (2) 2
hiv-1 - physiology (2) 2
human-immunodeficiency-virus (2) 2
in-vivo (2) 2
indinavir - administration & dosage (2) 2
indinavir - therapeutic use (2) 2
interferon (2) 2
interferon-alpha - therapeutic use (2) 2
internal medicine (2) 2
lamivudine - administration & dosage (2) 2
lamivudine - therapeutic use (2) 2
latency (2) 2
liver cirrhosis (2) 2
pharmacology & pharmacy (2) 2
physiological aspects (2) 2
piperazines - pharmacokinetics (2) 2
polyethylene glycols - therapeutic use (2) 2
primary infection (2) 2
psi-7977 (2) 2
recombinant proteins - administration & dosage (2) 2
recombinant proteins - therapeutic use (2) 2
replication (2) 2
resistance (2) 2
reverse transcriptase inhibitors - administration & dosage (2) 2
reverse transcriptase inhibitors - therapeutic use (2) 2
ribavirin - administration & dosage (2) 2
ribavirin - therapeutic use (2) 2
rna, viral - blood (2) 2
spiro compounds - pharmacokinetics (2) 2
treatment outcome (2) 2
uridine monophosphate - administration & dosage (2) 2
uridine monophosphate - therapeutic use (2) 2
viral nonstructural proteins - antagonists & inhibitors (2) 2
viremia (2) 2
virus integration (2) 2
virus latency (2) 2
virus replication (2) 2
virus-infection (2) 2
zidovudine - administration & dosage (2) 2
zidovudine - therapeutic use (2) 2
activation (1) 1
administration, oral (1) 1
adverse events (1) 1
aids (1) 1
analysis (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9883, pp. 2100 - 2107
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9751, pp. 1467 - 1475
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 5, pp. 401 - 408
Summary Background Protease inhibitors have improved treatment of infection with hepatitis C virus (HCV), but dosing, a low barrier to resistance, drug... 
Infectious Disease | PSI-7977 | INFECTIOUS DISEASES | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | BOCEPREVIR | INHIBITORS | Recombinant Proteins - therapeutic use | Uridine Monophosphate - administration & dosage | Nausea - chemically induced | Humans | Middle Aged | Hepatitis C, Chronic - virology | Hepacivirus - pathogenicity | Male | Secondary Prevention | Polyethylene Glycols - therapeutic use | Young Adult | Time Factors | Ribavirin - administration & dosage | Adult | Female | Headache - chemically induced | Uridine Monophosphate - therapeutic use | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | RNA, Viral - analysis | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Adolescent | Liver Cirrhosis - pathology | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Protease inhibitors | Proteases | Gastrointestinal diseases | Clinical trials | Product development | Genetic aspects | Interferon | Hepatitis C | Health aspects | Liver cirrhosis | Viral antigens
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2013, Volume 368, Issue 1, pp. 34 - 44
In this small, preliminary study of sofosbuvir, a nucleotide inhibitor of HCV polymerase, treatment with sofosbuvir and ribavirin, without peginterferon, was... 
GENOTYPE 1 | PSI-7977 | MEDICINE, GENERAL & INTERNAL | VIRUS-INFECTION | THERAPY | REPLICATION | RESISTANCE | REPLICON RNA-SYNTHESIS | COMBINATION | TREATMENT-NAIVE PATIENTS | PROTEASE | Recombinant Proteins - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | Recombinant Proteins - adverse effects | Polyethylene Glycols - therapeutic use | Viral Load | Adult | Female | RNA, Viral - metabolism | Uridine Monophosphate - adverse effects | Drug Therapy, Combination | Uridine Monophosphate - therapeutic use | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Hemoglobins - metabolism | Genotype | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Interferon-alpha - adverse effects | Viral Nonstructural Proteins - antagonists & inhibitors | Sofosbuvir | Drugs | Dose-response relationship (Biochemistry) | Antiviral agents | Usage | Patient outcomes | Dosage and administration | Product/Service Evaluations | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Hepatitis | Interferon | Infections | Index Medicus | Abridged Index Medicus
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 7/1998, Volume 95, Issue 15, pp. 8869 - 8873
The presence of latently infected, resting CD4 T cells carrying replication-competent HIV-1 has been demonstrated in chronically infected individuals who are... 
T lymphocytes | Highly active antiretroviral therapy | HIV | Viremia | Viruses | Disease reservoirs | Infections | Symptoms | HIV 1 | Blood plasma | Primary infection | HAART therapy | Latency | RESPONSES | PLASMA | MULTIDISCIPLINARY SCIENCES | latency | IN-VIVO | primary infection | AIDS | HUMAN-IMMUNODEFICIENCY-VIRUS | Physiological aspects | Research | T cells | HIV infection
Journal Article
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 05/2006, Volume 46, Issue 5, pp. 577 - 587
Journal Article
Consultant, ISSN 0010-7069, 1997, Volume 37, Issue 5, pp. 1243 - 1244
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.